about
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlightCirculating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites.Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy.Urinary interleukin-1β levels among gynecological patients.Cancer odor in the blood of ovarian cancer patients: a retrospective study of detection by dogs during treatment, 3 and 6 months afterwardProteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients.Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancerHighly-accurate metabolomic detection of early-stage ovarian cancer.Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.Promoter DNA methylation is associated with KLF11 expression in epithelial ovarian cancer.Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies.Cell Cycle Model System for Advancing Cancer Biomarker Research.Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissues.Assessment of ovarian cancer conditions from exhaled breath.Detection of the ovarian cancer biomarker CA-125 using chemiluminescence resonance energy transfer to graphene quantum dots.
P2860
Q30490448-E4BAAA62-C432-4114-A307-9824A5BFED69Q33751321-F0FCDA82-EBF5-458B-9834-6E73E96E375CQ33946367-0232922C-7E88-4F66-AB06-A4CCE48E0006Q34204891-86C8EEE1-16E4-4209-9831-4907D6D909ACQ34584672-6A1AF94B-891D-4FAD-9CD8-34A6A85B6C26Q34974418-9F38E9EB-7F7D-49EC-BEEA-BA4FE986ACEAQ35104034-B1715425-FBDD-46EA-9D90-6167BAE3E0BFQ35551874-18CA68EE-1AED-4A76-AD9E-C0C5EC3EDD1BQ36285567-1F4FBC29-B0D8-42C0-86EC-FD184946BD15Q36603235-553AFABC-D96D-4E7A-BDDA-212B32398AC1Q36949580-4A0C938A-E99E-434F-8DBA-BB75FF69127FQ38880302-F4CA9157-6166-4302-A098-39DE673A3E7AQ40798586-B8C0D2BF-8445-4F35-91C3-F5EF7ADE1610Q47262784-9EB956BC-B3D9-432C-9DEE-6783F3908208Q49163347-9E3B8B79-D8D3-42E0-945F-FEF38D7081C7Q51701639-AA652017-67E8-4D6B-BD3B-C89E118746A5Q53654158-68172F68-4378-4849-8A1C-CCBDBF80903F
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biomarkers for early detection of ovarian cancer.
@en
type
label
Biomarkers for early detection of ovarian cancer.
@en
prefLabel
Biomarkers for early detection of ovarian cancer.
@en
P2093
P2860
P356
P1433
P1476
Biomarkers for early detection of ovarian cancer.
@en
P2093
Christina Curtin
David Fishman
Linus Chuang
Long Nguyen
Mazdak Momeni
Pierre Gordon
Segundo Joel Cardenas-Goicoechea
P2860
P304
171-85; quiz 186-7
P356
10.2217/WHE.13.2
P577
2013-03-01T00:00:00Z